Lifeward Shareholders Back Oramed Partnership to Diversify Into Biotech

Lifeward Ltd. has received shareholder approval to proceed with a transformative strategic partnership with Oramed Pharmaceuticals, marking a significant pivot for the medical device company. The deal represents a calculated diversification strategy, enabling Lifeward to extend beyond its established rehabilitation technology portfolio into biotechnology while securing substantial capital infusion of up to $47 million. Under the partnership terms, Oramed assumes responsibility for managing and funding the clinical development of its proprietary POD™ oral delivery technology platform, while Lifeward continues driving profitability from its flagship ReWalk® and AlterG® product lines.

This strategic alliance reflects a broader industry trend of medical device companies seeking to expand their pipelines and revenue streams through partnerships with emerging biotech firms. For Lifeward, the arrangement offers an attractive balance—accessing cutting-edge pharmaceutical delivery technology while maintaining operational focus on its proven, revenue-generating devices. The partnership essentially allows Lifeward to build exposure to the biotechnology sector without the burden of independently funding early-stage pharmaceutical development, a typically capital-intensive endeavor.

Key Details of the Strategic Partnership

The newly approved partnership restructures how both companies will operate moving forward. Oramed Pharmaceuticals, known for its innovative oral delivery technology, will retain full control and funding responsibility for the POD™ platform's clinical development pipeline. This arrangement protects Lifeward's balance sheet from the substantial costs and risks associated with biotech R&D while still providing equity upside from Oramed's potential commercial success.

Key transaction elements include:

• Capital injection of up to $47 million to strengthen Lifeward's financial position
• Oramed maintains operational control of POD™ platform development and clinical trials
• Lifeward retains focus on ReWalk® exoskeleton and AlterG® anti-gravity treadmill product lines
• Strategic partnership structure rather than full acquisition, preserving both companies' distinct identities

The shareholder vote represents an important validation of management's diversification thesis. By maintaining dual business streams—profitable medical devices and emerging biotech assets—Lifeward positions itself to benefit from multiple growth vectors. The ReWalk® and AlterG® franchises provide near-term cash generation, while the Oramed partnership offers longer-term upside potential if the POD™ platform successfully advances through clinical development and reaches commercialization.

Market Context and Competitive Landscape

The strategic partnership arrives at an inflection point for the medical device and biotech sectors. Medical device manufacturers face persistent margin pressure from healthcare cost containment measures, making diversification into higher-margin pharmaceutical delivery systems strategically compelling. The partnership demonstrates Lifeward's recognition that device-only positioning may offer limited growth ceiling in an increasingly competitive marketplace.

Oramed Pharmaceuticals' POD™ technology represents a significant competitive advantage in the oral drug delivery space, where companies have traditionally struggled with peptide and protein absorption challenges. Oral delivery solutions command premium valuations in biotech because they improve patient compliance compared to injectable alternatives. The partnership effectively gives Lifeward access to this attractive market segment without requiring the company to develop proprietary delivery technology internally—a process that typically consumes years and hundreds of millions in R&D spending.

The broader context reveals industry consolidation and partnership trends accelerating across medtech and biotech sectors. Companies increasingly recognize that organic growth alone may prove insufficient, particularly amid:

• Regulatory scrutiny of drug pricing and device reimbursement
• Increasing R&D costs for clinical development
• Market consolidation reducing competitive differentiation
• Investor demand for diversified revenue streams

Lifeward's approach—leveraging a partnership rather than acquisition—offers a lower-risk alternative to the all-or-nothing M&A strategies that have backfired for some medtech peers. The capital injection of $47 million provides immediate balance sheet strengthening without excessive debt assumption, important for maintaining financial flexibility.

Investor Implications and Forward Outlook

For Lifeward shareholders, the partnership approval carries several important implications. First, the capital infusion strengthens the company's financial runway, critical for sustaining profitability initiatives on core ReWalk® and AlterG® platforms while building infrastructure for biotech exposure. Second, the arrangement provides equity upside participation without forcing Lifeward to directly bear Oramed's development risks—a favorable risk-reward profile.

Third, the partnership demonstrates execution capability on strategic initiatives, potentially improving investor sentiment toward management's broader transformation strategy. Medical device investors often penalize companies perceived as lacking growth catalysts; the Oramed partnership addresses this concern by creating tangible exposure to emerging biotech opportunities.

The POD™ platform addresses a substantial market opportunity in oral peptide and protein delivery, a sector estimated in the billions annually. If Oramed successfully advances its clinical programs and achieves commercialization, Lifeward gains proportional upside exposure. Conversely, the partnership structure limits downside risk—if Oramed's development disappoints, Lifeward maintains unimpaired operational focus on its core device franchises.

Investors should monitor several metrics going forward: Lifeward's quarterly profitability progress on existing products, Oramed's clinical development milestones for POD™, and any announcements regarding additional partnerships or asset acquisitions. The partnership may also create opportunities for future expansion if management demonstrates successful integration of biotech opportunities into Lifeward's business model.

With shareholder approval now secured, Lifeward enters an important execution phase. The company must simultaneously optimize profitability from mature device platforms while building organizational capabilities to evaluate and integrate emerging biotech assets. This dual-track approach—combining harvesting value from established products with strategic exploration of emerging opportunities—reflects increasingly sophisticated capital allocation strategies within the medtech sector. For investors evaluating Lifeward, the partnership signals management confidence in the company's ability to thrive in an evolving healthcare landscape where diversification increasingly drives shareholder returns.